Sep. 13, 2023—Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.
Jun. 22, 2023—Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.
Mar. 16, 2023—Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.
Feb. 2, 2023— by Bill Snyder More than a million people in the United States are living with HIV, the virus that causes AIDS. One-fifth of them have been co-infected by the hepatitis C virus (HCV), which attacks the liver. Curative drugs for HCV are available, but many people don’t know they’ve been infected. And if they...
Aug. 25, 2022—An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.
Mar. 24, 2022—Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...